Philip Morris Receives FDA Advisory Committee Recommendation Supporting Modified Risk Claims For IQOS; FDA Concludes "Evidence Continues To Support The Modified Exposure Claim That 'Scientific Studies Have Shown That Switching Completely From Conventional Cigarettes To The IQOS System Significantly Reduces Your Body's Exposure To Harmful Or Potentially Harmful Chemicals'"

Author: Benzinga Newsdesk | October 08, 2025 10:54am

• A pioneer in modified risk tobacco products, Philip Morris International is the only company to have received a modified risk marketing claim for an electronic nicotine device.
• FDA concludes "Evidence continues to support the modified exposure claim that ‘Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body's exposure to harmful or potentially harmful chemicals.'"

Experts from Philip Morris International Inc. (NYSE:PM) presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC). The committee, comprised of independent scientific researchers, provides nonbinding recommendations to the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products (CTP).

The full-day meeting on October 7 was part of the FDA's customary review of PMI's request to continue marketing versions of its IQOS heated tobacco products in the U.S. as modified risk tobacco products (MRTPs), a necessary step while FDA completes its review of pending applications for IQOS ILUMA (a later version of the IQOS models that are currently authorized by the FDA) to reach and transition even more legal-age adults away from combustible cigarettes.

Posted In: PM